Nominal 
HONG KONG ECONOMIC TIMES, August 24 – Fosun Pharma (02696) announced a net profit of RMB 430 million (in Renminbi, the same below) for the six months ended June 30, an increase of 10.3% year-on-year; earnings per share were 79 cents, with no interim dividend distributed.
The group stated that revenue reached RMB 3.588 billion, up 27.3%, primarily driven by drug sales, research and development services provided to customers, and licensing income; gross profit was RMB 2.768 billion, up 25.9%; R&D expenses were approximately RMB 1.45 billion, an increase of about RMB 460 million, mainly used to strengthen investment in innovative R&D projects to accelerate innovation transformation. Pre-tax profit was RMB 498 million, up 26.4%. (wh)
*For details of the results, please refer to the company's official announcement
The group stated that revenue reached RMB 3.588 billion, up 27.3%, primarily driven by drug sales, research and development services provided to customers, and licensing income; gross profit was RMB 2.768 billion, up 25.9%; R&D expenses were approximately RMB 1.45 billion, an increase of about RMB 460 million, mainly used to strengthen investment in innovative R&D projects to accelerate innovation transformation. Pre-tax profit was RMB 498 million, up 26.4%. (wh)
*For details of the results, please refer to the company's official announcement